Merck discontinues phase 3 KeyVibe─010 trial of coformulation of vibostolimab and pembrolizumab as adjuvant treatment ...
Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, …